Detalhe da pesquisa
1.
MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer.
Int J Mol Sci
; 25(1)2023 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38203393
2.
DUSP4 enhances therapeutic sensitivity in HER2-positive breast cancer by inhibiting the G6PD pathway and ROS metabolism by interacting with ALDOB.
Transl Oncol
; 46: 102016, 2024 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38843658
3.
Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Cancer Med
; 13(2): e6955, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38379328
4.
Cross-talk of four types of RNA modification proteins with adenosine reveals the landscape of multivariate prognostic patterns in breast cancer.
Front Genet
; 13: 943378, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36118888